Pioneering multivalent mRNA-LNP vaccine provides breakthrough protection against C. difficile infection

Researchers from several U.S. institutions have developed an mRNA vaccine that has proven effective in protecting mice against intestinal Clostridioides difficile bacterial infections. In their paper published in Science, the team describes how they used mRNA technology to develop a multipronged vaccine to target several proteins needed by bacteria to cause gut disorders and how well it performed in mouse testing. The research is unique in using a multivalent mRNA-LNP vaccine to target a particularly difficult and persistent bacterial infection — Clostridioides difficile infection (CDI). CDI can cause severe gastrointestinal disease, often fatal, especially in hospital settings. This research represents a breakthrough because it leverages the rapidly advancing mRNA technology, traditionally associated with viral vaccines, to combat a bacterial infection that involves toxins as its main pathogenic drivers. The key achievement of this study is the development and validation of an mRNA-based vaccine that can target multiple virulence factors (TcdA, TcdB, PPEP-1,...